Golden Eagle Dynamic Hypergrowth ETF (HYP)

As a Risk Manager reviewing HYP, the Morningstar portfolio risk score of 110 is a flashing red light. Sitting squarely in the Extreme risk bracket, the fund exhibits a 1-year beta of 1.85 against a category norm of 1.0 to 1.2. With a Sharpe ratio of 0.22, investors are taking on massive volatility without adequate compensation. The downside capture and max drawdown metrics confirm it amplifies losses significantly more than gains.

From our hedge fund PM seat, looking at the Q1 2026 filings for HYP reveals total institutional ownership of just $1.41M across 2 funds. While 1 fund opened a new position and another increased theirs, the absolute capital commitment remains minuscule for a product trading with a market cap around $72.4M. Liquidity is thin, with daily volumes hovering around 3,589 shares, making large block execution challenging.

On the biotech analytics side, I am tracking HYP's top holdings, which heavily feature clinical-stage and specialized names like Adaptive Biotechnologies, Stoke Therapeutics, and Insmed, each weighted around 2.52%. These equity positions expose the fund directly to binary clinical trial readouts and regulatory bottlenecks, explaining why the overall equity risk profile is so erratic.

On our quant desk, the portfolio metrics show a staggering 127.04% portfolio turnover rate paired with an 0.85% expense ratio. This high-churn strategy attempts to capture momentum across large growth categories, but the resulting negative total return since inception (-6.19% vs SandP 500's +3.16%) suggests the dynamic rebalancing is getting whipsawed by broader market cycles.

Reviewing market sentiment across community boards, retail investors note that despite a brief 3-month spring rally (+30.3% from 03/31/26 to 06/30/26), subsequent months like July saw a brutal -21.7% drawdown. This boom-and-bust cycle alienates conservative allocators and requires a strong stomach for anyone attempting short-term tactical entries.